INVESTIGATING THE INTERPLAY: UNRAVELLING THE IL-6 CONNECTION AND INTRAVENOUS METHYLPREDNISOLONE’S IMPACT ON RECTUS MUSCLE IN THYROID EYE DISEASE
Article Sidebar
-
Thyroid Eye Disease, Intravenous Corticosteroid Therapy, Rectus Muscle, Extraocular Muscle, IL-6
Abstract
Introduction & Objective: Intravenous corticosteroid has been used in management of Thyroid Eye Diseases (TED). Many previous studies have shown the therapeutic benefits of corticosteroid therapy. Recently, the efficacy of high-dose intravenous corticosteroid pulse therapy has been reported. Recent studies have highlighted the potential role of interleukin-6 (IL-6) in the pathogenesis of TED. However, the correlation between IL-6 levels and the effects of IVMP on rectus muscles in patients with TED remains unclear. This study aims to investigate the correlation between IL-6 levels and the effects of IVMP on rectus muscles in patients with TED
Methods : Retrospective analysis were used in the data collection of patients with active Thyroid Eye Disease who undergone high-dose intravenous methylprednisolone pulse therapy (500mg per week for 6 successive weeks) at Sardjito General Hospital between January 2022 and December 2022. Data on the Level of IL-6 were obtained at the start of treatment, and quantitative computed tomography (CT) of the orbit and were performed before and after treatments. Demographics data were presented in tables and graphs.
Results : This study included 62 eyes of 31 patients (61,3% female) with mean age of 37.8±13.47 years old. There was significant inverse correlation in levels of IL-6 and ?SR (P=0.037) which implies a reduced effect of IVMP on SR. However, other statistical analyses on different rectus muscle groups bare no statistical significance.
Conclusion : The use of IL-6 as a single predictor of responsiveness of the treatment of high dose intravenous methylprednisolone is not endorsed by the result of this study. However, further studies with better established level of IL-6 both pre and post treatment, and more inclusive parameters are needed to better provide better understanding on the role of IL-6.
Full text article
References
Men CJ, Kossler AL, Wester ST. Updates on the understanding and management of thyroid eye disease. Ther Adv Ophthalmol. 2021 Jun 30; 13:25158414211027760.doi:10.1177/25158414211027760. PMID: 34263138; PMCID: PMC8252358.
Shah SS, Patel BC. Thyroid Eye Disease. [Updated 2022 May 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK582134/
Ueland, H. O., Ueland, G. Å., Løvås, K., Breivk, L. E., Thrane, A. S., Meling Stokland, A., Rødahl, E., & Husebye, E. S. (2022). Novel inflammatory biomarkers in thyroid eye disease, European Journal of Endocrinology, 187(2), 293-300. Retrieved May 30, 2023, from https://doi.org/10.1530/EJE-22-0247
Bouzehouane, N., Borson-Chazot, F., Abeillon, J., & Caron, P. (2021). Treatment of moderate to severe orbitopathy: Current modalities and perspectives. Annales d’Endocrinologie, 82(2), 92–98. https://doi.org/10.1016/J.ANDO.2021.02.001
Salvi M, Vannucchi G, Campi I, Curro N, Dazzi,D, & Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P. Treatment of graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open study. European journal of endocrinology / European Federation of Endocrine Societies. 2007. 156. 33-40. 10.1530/eje.1.02325.
McAlinden C. An overview of thyroid eye disease. Eye Vis (Lond). 2014 Dec 10;1:9. doi: 10.1186/s40662-014-0009-8. PMID: 26605355; PMCID: PMC4655452.
Chandra P, Sudhalkar A, Jalali S, Pesala V, Narayanan R, Sahu C, Chhablani J. Echographic study of extraocular muscle thickness in normal Indian population. Saudi J Ophthalmol. 2014 Oct;28(4):281-6. doi: 10.1016/j.sjopt.2014.05.003. Epub 2014 Jun 6. PMID: 25473344; PMCID: PMC4250497.
Higashiyama T, Nishida Y, Ohji M. Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy. Clin Ophthalmol. 2016;10:721-729 https://doi.org/10.2147/OPTH.S105096
Young SM, Lim AYN, Lang SS, Lee KO, Sundar G. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease. Orbit. 2019 Oct;38(5):362-369. doi: 10.1080/01676830.2018.1553189. Epub 2018 Dec 12. PMID: 30540214.
Rashad, R.; Pinto, R.; Li, E.; Sohrab, M.; Distefano, A.G. Thyroid Eye Disease. Life 2022, 12, 2084. https://doi.org/10.3390/ life12122084
Strianese D. Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1):S56-S59. doi:10.1097/IOP.0000000000001131
Higashiyama T, Nishida Y, Ohji M. Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy. Clin Ophthalmol. 2016;10:721-729
https://doi.org/10.2147/OPTH.S105096
Liu X, Wang S, Qin L, et al. Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy. Exp Ther Med. 2016;12(2):901-908. doi:10.3892/etm.2016.3446
Singh, M. Role of Intravenous Methylprednisolone in Moderate to Severe Thyroid Associated Orbitopathy (Tao) in Indians: A Tertiary Care Institute Study. Medical & Surgical Ophthalmology Research (2018): n. pag.
Authors
Copyright (c) 2024 dr. Rangga Athallah Fajar, Prof. Dr. dr. Agus Supartoto, Sp.M(K) , Dr. dr. Purjanto Tepo Utomo, Sp.M(K), dr. Banu Aji Dibyasakti, Sp.M, dr. Irene Titin Darajati, Sp.M
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.